Basic information
Biomarker: endoglin
Histology type: endometrial carcinoma
Stage: advanced stage
Cohort characteristics
Region: Silesia
Followed up time :
Subgroup 1 name : endometrioid endometrial cancer
Subgroup 1 number: 45
Subgroup 2 name: without neoplastic changes control group
Subgroup 2 number: 15
Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
---|---|---|---|---|---|---|---|---|
60 | endometrioid endometrial cancer | 45 | without neoplastic changes | 15 |
Sample information
Conclusion: Endoglin can be considered a valuable complementary molecular marker, allowing to visualize the advancement of the cancer process, including endometrial cancer.
Sample type : tissue
Sample method: immunohistochemistry
Expression pattern : expression(positively stained)
Expression elevation: The intensity of staining was measured as the optical density of the reaction product in each positively stained cell. The image analysis program NISAR (Nikon) was used to calculate the average optical density.
Disease information
Related information
Funtion Uniprot: Vascular endothelium glycoprotein that plays an important role in the regulation of angiogenesis (PubMed:21737454, PubMed:23300529). Required for normal structure and integrity of adult vasculature (PubMed:7894484). Regulates the migration of vascular endothelial cells (PubMed:17540773). Required for normal extraembryonic angiogenesis and for embryonic heart development (By similarity). May regulate endothelial cell shape changes in response to blood flow, which drive vascular remodeling and establishment of normal vascular morphology during angiogenesis (By similarity). May play a critical role in the binding of endothelial cells to integrins and/or other RGD receptors (PubMed:1692830). Acts as TGF-beta coreceptor and is involved in the TGF-beta/BMP signaling cascade that ultimately leads to the activation of SMAD transcription factors (PubMed:8370410, PubMed:21737454, PubMed:22347366, PubMed:23300529). Required for GDF2/BMP9 signaling through SMAD1 in endothelial cells and modulates TGFB1 signaling through SMAD3 (PubMed:21737454, PubMed:22347366, PubMed:23300529)
UniProt ID: P17813
UniProt Link: https://www.uniprot.org/uniprotkb/P17813/entry
Molecular function from UniProt:
Tissue specificity from UniProt: Detected on umbilical veil endothelial cells (PubMed:10625079). Detected in placenta (at protein level) (PubMed:1692830). Detected on endothelial cells (PubMed:1692830).
Subcellular UniProt: #Cell membrane #Membrane
Recommended name: Endoglin
Gene name from HGNC: ENG (CD105, END, HHT1, ORW, ORW1)
CD antigen name: CD105
HPA class: Cancer-related genes Candidate cardiovascular disease genes CD markers Disease related genes Human disease related genes Plasma proteins
AlphaFold DB: P17813
AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P17813
HPA link: https://www.proteinatlas.org/ENSG00000106991-ENG
Tissue specificity RNA from HPA: Tissue enhanced (heart muscle)
Tissue expression from HPA: Selective expression in endothelial cells and placental trophoblasts.
Single cell type specificity Cell type enhanced (Peritubular cells, Hepatic stellate cells, Endothelial cells, Leydig cells, Adipocytes, Syncytiotrophoblasts, Theca cells, Extravillous trophoblasts)
Immune cell specificity: Group enriched (intermediate monocyte, non-classical monocyte, classical monocyte, myeloid DC, NK-cell)
Subcellular summary HPA Located in Nuclear bodies, Plasma membrane (Single cell variability)
Cancer prognostic summary HPA Prognostic marker in liver cancer (favorable), renal cancer (unfavorable) and head and neck cancer (favorable)
Pathology link: https://www.proteinatlas.org/ENSG00000106991-ENG/pathology
Pathology endo: https://www.proteinatlas.org/ENSG00000106991-ENG/pathology/endometrial+cancer
Expression figure legend: expression of endoglin
Expression figure link: https://www.eurekaselect.com/article/94828
Phenotype ID: 187300
Disease: Telangiectasia, hereditary hemorrhagic, 1 (HHT1)
Note1: The disease is caused by variants affecting the gene represented in this entry
Note2: HHT TELANGIECTASIA, HEREDITARY HEMORRHAGIC, OF RENDU, OSLER, AND WEBER OSLER-RENDU-WEBER DISEASE ORW DISEASE
OMIM: 131195;187300;
OMIM link1: https://www.omim.org/entry/187300
OMIM link2: https://www.omim.org/entry/131195;
Phenotype: TELANGIECTASIA, HEREDITARY HEMORRHAGIC, TYPE 1; HHT1
HGNC ID: HGNC:3349
HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3349